ArticleMethods in molecular biology (Clifton, N.J.)2025
IP6 Kinase Inhibitor Screening Assays.
Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inositol pyrophosphates, such as 5-diphosphoinositol pentakisphosphate (IP7), play crucial roles in various biological processes. Pharmacologic inhibition of IP6K has potential therapeutic benefits for treating type II diabetes, venous thrombosis, chronic kidney disease, and psychiatric disorders. This chapter describes the identification of IP6K inhibitors through kinase-activity-based high-throughput assays and dose-response assay. Additionally, it details cell-based assays on the determination of the effect of IP6K inhibitors on IP7 production in HCT116 cells and the binding of IP6K inhibitors to IP6K inside cells through cellular thermal shift assays (CETSAs). These robust assays provide a foundation for further exploration of IP6K inhibitors in various disease states.
Indexed as
Identifiers
40879992What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.